Their research gives oncologists a better shot at overcoming the problems of drug resistance, toxicity to patients, and a host of other barriers to consistently achieving successful gene therapy for cancer
An international study was launched when researchers found that another inhibitor for advanced cancers, called OTS167, had a negative outcome in a clinical trial